Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 94


Antiretroviral Activity of AMD11070 (An Orally Administered CXCR4 Entry Inhibitor): Results of NIH/NIAID AIDS Clinical Trials Group Protocol A5210.

Johnson VA, Cramer YS, Rosenkranz SL, Becker S, Klingman KL, Kallungal B, Coakley E, Acosta EP, Calandra G, Saag MS; NIH/NIAID AIDS Clinical Trials Group A5210 Protocol Team.

AIDS Res Hum Retroviruses. 2019 Aug;35(8):691-697. doi: 10.1089/AID.2018.0256. Epub 2019 Jun 18.


First Trimester Prenatal Care Initiation Among Hispanic Women Along the U.S.-Mexico Border.

Selchau K, Babuca M, Bower K, Castro Y, Coakley E, Flores A, Garcia JO, Reyes MLF, Rojas Y, Rubin J, Samuels D, Shattuck L.

Matern Child Health J. 2017 Dec;21(Suppl 1):11-18. doi: 10.1007/s10995-017-2374-0.


Change Is Hard: What Really Happens When You Try to Implement a New Care Model.

Grantham S, Knowles T, Nesin N, Truesdell N, Coakley E.

Fam Pract Manag. 2017 Nov/Dec;24(6):10-15. No abstract available.


Pharmacokinetics of Tacrolimus and Cyclosporine in Liver Transplant Recipients Receiving 3 Direct-Acting Antivirals as Treatment for Hepatitis C Infection.

Badri PS, Parikh A, Coakley EP, Ding B, Awni WM, Dutta S, Menon RM.

Ther Drug Monit. 2016 Oct;38(5):640-5. doi: 10.1097/FTD.0000000000000315.


Assessment of Enterococcus Levels in Recreational Beach Sand Along the Rhode Island Coast.

Coakley E, Parris AL, Wyman A, Latowsky G.

J Environ Health. 2016 Apr;78(8):12-7.


Serum miR-122 may serve as a biomarker for response to direct acting antivirals: effect of paritaprevir/R with dasabuvir or ombitasvir on miR-122 in HCV-infected subjects.

Waring JF, Dumas EO, Abel S, Coakley E, Cohen DE, Davis JW, Podsadecki T, Dutta S.

J Viral Hepat. 2016 Feb;23(2):96-104. doi: 10.1111/jvh.12470. Epub 2015 Oct 5.


Distribution Analyzer, a methodology for identifying and clustering outlier conditions from single-cell distributions, and its application to a Nanog reporter RNAi screen.

Gingold JA, Coakley ES, Su J, Lee DF, Lau Z, Zhou H, Felsenfeld DP, Schaniel C, Lemischka IR.

BMC Bioinformatics. 2015 Jul 22;16:225. doi: 10.1186/s12859-015-0636-7.


Pharmacokinetics and dose recommendations for cyclosporine and tacrolimus when coadministered with ABT-450, ombitasvir, and dasabuvir.

Badri P, Dutta S, Coakley E, Cohen D, Ding B, Podsadecki T, Bernstein B, Awni W, Menon R.

Am J Transplant. 2015 May;15(5):1313-22. doi: 10.1111/ajt.13111. Epub 2015 Feb 23.


Drug-drug interaction profile of the all-oral anti-hepatitis C virus regimen of paritaprevir/ritonavir, ombitasvir, and dasabuvir.

Menon RM, Badri PS, Wang T, Polepally AR, Zha J, Khatri A, Wang H, Hu B, Coakley EP, Podsadecki TJ, Awni WM, Dutta S.

J Hepatol. 2015 Jul;63(1):20-9. doi: 10.1016/j.jhep.2015.01.026. Epub 2015 Jan 31.


Patterns and predictors of malaria care-seeking, diagnostic testing, and artemisinin-based combination therapy for children under five with fever in Northern Nigeria: a cross-sectional study.

Millar KR, McCutcheon J, Coakley EH, Brieger W, Ibrahim MA, Mohammed Z, Bassi A, Sambisa W.

Malar J. 2014 Nov 21;13:447. doi: 10.1186/1475-2875-13-447.


An interferon-free antiviral regimen for HCV after liver transplantation.

Kwo PY, Mantry PS, Coakley E, Te HS, Vargas HE, Brown R Jr, Gordon F, Levitsky J, Terrault NA, Burton JR Jr, Xie W, Setze C, Badri P, Pilot-Matias T, Vilchez RA, Forns X.

N Engl J Med. 2014 Dec 18;371(25):2375-82. doi: 10.1056/NEJMoa1408921. Epub 2014 Nov 11.


Determination of viral tropism by genotyping and phenotyping assays in Brazilian HIV-1-infected patients.

Arruda LB, Araújo ML, Martinez ML, Gonsalez CR, Duarte AJ, Coakley E, Lie Y, Casseb J.

Rev Inst Med Trop Sao Paulo. 2014 Jul-Aug;56(4):287-90.


Treatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin.

Feld JJ, Kowdley KV, Coakley E, Sigal S, Nelson DR, Crawford D, Weiland O, Aguilar H, Xiong J, Pilot-Matias T, DaSilva-Tillmann B, Larsen L, Podsadecki T, Bernstein B.

N Engl J Med. 2014 Apr 24;370(17):1594-603. doi: 10.1056/NEJMoa1315722. Epub 2014 Apr 10.


CCR5 expression is reduced in lymph nodes of HIV type 1-infected women, compared with men, but does not mediate sex-based differences in viral loads.

Meditz AL, Folkvord JM, Lyle NH, Searls K, Lie YS, Coakley EP, McCarter M, Mawhinney S, Connick E.

J Infect Dis. 2014 Mar;209(6):922-30. doi: 10.1093/infdis/jit575. Epub 2013 Oct 31.


HIV-1 tropism testing in subjects achieving undetectable HIV-1 RNA: diagnostic accuracy, viral evolution and compartmentalization.

Pou C, Codoñer FM, Thielen A, Bellido R, Pérez-Álvarez S, Cabrera C, Dalmau J, Curriu M, Lie Y, Noguera-Julian M, Puig J, Martínez-Picado J, Blanco J, Coakley E, Däumer M, Clotet B, Paredes R.

PLoS One. 2013 Aug 1;8(8):e67085. doi: 10.1371/journal.pone.0067085. Print 2013.


A case-based reasoning system for genotypic prediction of HIV-1 co-receptor tropism.

Evans MC, Paquet AC, Huang W, Napolitano L, Frantzell A, Toma J, Stawiski EW, Goetz MB, Petropoulos CJ, Whitcomb J, Coakley E, Haddad M.

J Bioinform Comput Biol. 2013 Aug;11(4):1350006. doi: 10.1142/S0219720013500066. Epub 2013 Apr 7.


HIV Drug Resistance Profiles and Clinical Outcomes in Patients with Viremia Maintained at Very Low Levels.

Jordan MR, Winsett J, Tiro A, Bau V, Berbara RS, Rowley C, Bellosillo N, Wanke C, Coakley EP.

World J AIDS. 2013 Jun;3(2):71-78.


The national AgeWISE pilot.

Lee SM, Coakley EE, Blakeney BA, Brandt LK, Rideout ML, Dahlin C.

J Nurs Adm. 2012 Jul-Aug;42(7-8):356-60. doi: 10.1097/NNA.0b013e318261939f.


Vicriviroc resistance decay and relative replicative fitness in HIV-1 clinical isolates under sequential drug selection pressures.

Tsibris AM, Hu Z, Paredes R, Leopold KE, Putcharoen O, Schure AL, Mazur N, Coakley E, Su Z, Gulick RM, Kuritzkes DR.

J Virol. 2012 Jun;86(12):6416-26. doi: 10.1128/JVI.00286-12. Epub 2012 Apr 4.


Predictive value of HIV-1 replication capacity and phenotypic susceptibility scores in antiretroviral treatment-experienced patients.

Bedimo R, Kyriakides T, Brown S, Weidler J, Lie Y, Coakley E, Holodniy M.

HIV Med. 2012 Jul;13(6):345-51. doi: 10.1111/j.1468-1293.2011.00981.x. Epub 2012 Jan 26.


Short communication: Phenotypic protease inhibitor resistance and cross-resistance in the clinic from 2006 to 2008 and mutational prevalences in HIV from patients with discordant tipranavir and darunavir susceptibility phenotypes.

Bethell R, Scherer J, Witvrouw M, Paquet A, Coakley E, Hall D.

AIDS Res Hum Retroviruses. 2012 Sep;28(9):1019-24. doi: 10.1089/AID.2011.0242. Epub 2012 Mar 23.


HIV-1 clinical isolates resistant to CCR5 antagonists exhibit delayed entry kinetics that are corrected in the presence of drug.

Putcharoen O, Lee SH, Henrich TJ, Hu Z, Vanichanan J, Coakley E, Greaves W, Gulick RM, Kuritzkes DR, Tsibris AM.

J Virol. 2012 Jan;86(2):1119-28. doi: 10.1128/JVI.06421-11. Epub 2011 Nov 16.


Transmitted drug resistance among antiretroviral-naive patients with established HIV type 1 infection in Santo Domingo, Dominican Republic and review of the Latin American and Caribbean literature.

Myers JE, Taylor BS, Rojas Fermín RA, Reyes EV, Vaughan C, José L, Javier C, Franco Estévez R, Donastorg Cabral Y, Batista A, Lie Y, Coakley E, Hammer SM, Brudney K.

AIDS Res Hum Retroviruses. 2012 Jul;28(7):667-74. doi: 10.1089/AID.2010.0355. Epub 2011 Sep 23. Review.


HLA-DR+ CD38+ CD4+ T lymphocytes have elevated CCR5 expression and produce the majority of R5-tropic HIV-1 RNA in vivo.

Meditz AL, Haas MK, Folkvord JM, Melander K, Young R, McCarter M, Mawhinney S, Campbell TB, Lie Y, Coakley E, Levy DN, Connick E.

J Virol. 2011 Oct;85(19):10189-200. doi: 10.1128/JVI.02529-10. Epub 2011 Aug 3.


Detection of inferred CCR5- and CXCR4-using HIV-1 variants and evolutionary intermediates using ultra-deep pyrosequencing.

Bunnik EM, Swenson LC, Edo-Matas D, Huang W, Dong W, Frantzell A, Petropoulos CJ, Coakley E, Schuitemaker H, Harrigan PR, van 't Wout AB.

PLoS Pathog. 2011 Jun;7(6):e1002106. doi: 10.1371/journal.ppat.1002106. Epub 2011 Jun 23.


Exposure to trauma and posttraumatic stress disorder symptoms in older veterans attending primary care: comorbid conditions and self-rated health status.

Durai UN, Chopra MP, Coakley E, Llorente MD, Kirchner JE, Cook JM, Levkoff SE.

J Am Geriatr Soc. 2011 Jun;59(6):1087-92. doi: 10.1111/j.1532-5415.2011.03407.x. Epub 2011 Jun 7.


Short communication prevalence of susceptibility to etravirine by genotype and phenotype in samples received for routine HIV type 1 resistance testing in the United States.

Picchio G, Vingerhoets J, Tambuyzer L, Coakley E, Haddad M, Witek J.

AIDS Res Hum Retroviruses. 2011 Dec;27(12):1271-5. doi: 10.1089/aid.2011.0049. Epub 2011 Jun 11.


Connection domain mutations in HIV-1 reverse transcriptase do not impact etravirine susceptibility and virologic responses to etravirine-containing regimens.

Gupta S, Vingerhoets J, Fransen S, Tambuyzer L, Azijn H, Frantzell A, Paredes R, Coakley E, Nijs S, Clotet B, Petropoulos CJ, Schapiro J, Huang W, Picchio G.

Antimicrob Agents Chemother. 2011 Jun;55(6):2872-9. doi: 10.1128/AAC.01695-10. Epub 2011 Apr 4.


Reanalysis of coreceptor tropism in HIV-1-infected adults using a phenotypic assay with enhanced sensitivity.

Wilkin TJ, Goetz MB, Leduc R, Skowron G, Su Z, Chan ES, Heera J, Chapman D, Spritzler J, Reeves JD, Gulick RM, Coakley E.

Clin Infect Dis. 2011 Apr 1;52(7):925-8. doi: 10.1093/cid/cir072.


Combined antiretroviral therapy and immune pressure lead to in vivo HIV-1 recombination with ancestral viral genomes.

Buzón MJ, Wrin T, Codoñer FM, Dalmau J, Phung P, Bonjoch A, Coakley E, Clotet B, Martinez-Picado J.

J Acquir Immune Defic Syndr. 2011 Jun 1;57(2):109-17. doi: 10.1097/QAI.0b013e318215ab0a.


Differences in reversion of resistance mutations to wild-type under structured treatment interruption and related increase in replication capacity.

Paquet AC, Baxter J, Weidler J, Lie Y, Lawrence J, Kim R, Bates M, Coakley E, Chappey C.

PLoS One. 2011 Jan 31;6(1):e14638. doi: 10.1371/journal.pone.0014638.


Remission in major depression: results from a geriatric primary care population.

Azar AR, Chopra MP, Cho LY, Coakley E, Rudolph JL.

Int J Geriatr Psychiatry. 2011 Jan;26(1):48-55. doi: 10.1002/gps.2485.


Three-year safety and efficacy of vicriviroc, a CCR5 antagonist, in HIV-1-infected treatment-experienced patients.

Wilkin TJ, Su Z, Krambrink A, Long J, Greaves W, Gross R, Hughes MD, Flexner C, Skolnik PR, Coakley E, Godfrey C, Hirsch M, Kuritzkes DR, Gulick RM.

J Acquir Immune Defic Syndr. 2010 Aug;54(5):470-6.


Comparison of standard PCR/cloning to single genome sequencing for analysis of HIV-1 populations.

Jordan MR, Kearney M, Palmer S, Shao W, Maldarelli F, Coakley EP, Chappey C, Wanke C, Coffin JM.

J Virol Methods. 2010 Sep;168(1-2):114-20. doi: 10.1016/j.jviromet.2010.04.030. Epub 2010 May 6.


Susceptibility of HIV-1 to tipranavir and other antiretroviral agents in treatment-experienced patients: The UTILIZE Study.

Baxter JD, Bhatti L, Coakley E, Bartczak J, McDonough M, Vinisko R, Piliero PJ.

Curr HIV Res. 2010 Jun;8(4):347-54.


Maraviroc versus efavirenz, both in combination with zidovudine-lamivudine, for the treatment of antiretroviral-naive subjects with CCR5-tropic HIV-1 infection.

Cooper DA, Heera J, Goodrich J, Tawadrous M, Saag M, Dejesus E, Clumeck N, Walmsley S, Ting N, Coakley E, Reeves JD, Reyes-Teran G, Westby M, Van Der Ryst E, Ive P, Mohapi L, Mingrone H, Horban A, Hackman F, Sullivan J, Mayer H.

J Infect Dis. 2010 Mar 15;201(6):803-13. doi: 10.1086/650697.


HIV replication capacity is an independent predictor of disease progression in persons with untreated chronic HIV infection.

Goetz MB, Leduc R, Wyman N, Kostman JR, Labriola AM, Lie Y, Weidler J, Coakley E, Bates M, Luskin-Hawk R; Long Term Monitoring Study (CPCRA060) Terry Beirn Community Programs for Clinical Research on AIDS.

J Acquir Immune Defic Syndr. 2010 Apr 1;53(4):472-9. doi: 10.1097/QAI.0b013e3181cae480.


An evidence-based nurse residency program in geropalliative care.

Lee SM, Coakley EE, Dahlin C, Carleton PF.

J Contin Educ Nurs. 2009 Dec;40(12):536-42; quiz 543-4. doi: 10.3928/00220124-20091119-01.


Response to vicriviroc in treatment-experienced subjects, as determined by an enhanced-sensitivity coreceptor tropism assay: reanalysis of AIDS clinical trials group A5211.

Su Z, Gulick RM, Krambrink A, Coakley E, Hughes MD, Han D, Flexner C, Wilkin TJ, Skolnik PR, Greaves WL, Kuritzkes DR, Reeves JD; AIDS Clinical Trials Group A5211 Team.

J Infect Dis. 2009 Dec 1;200(11):1724-8. doi: 10.1086/648090.


Comparison of human immunodeficiency virus type 1 tropism profiles in clinical samples by the Trofile and MT-2 assays.

Coakley E, Reeves JD, Huang W, Mangas-Ruiz M, Maurer I, Harskamp AM, Gupta S, Lie Y, Petropoulos CJ, Schuitemaker H, van 't Wout AB.

Antimicrob Agents Chemother. 2009 Nov;53(11):4686-93. doi: 10.1128/AAC.00229-09. Epub 2009 Aug 17.


Characterization of human immunodeficiency virus type 1 populations containing CXCR4-using variants from recently infected individuals.

Huang W, Toma J, Stawiski E, Fransen S, Wrin T, Parkin N, Whitcomb JM, Coakley E, Hecht FM, Deeks SG, Gandhi RT, Eshleman SH, Petropoulos CJ.

AIDS Res Hum Retroviruses. 2009 Aug;25(8):795-802. doi: 10.1089/aid.2008.0252.


Assessing human immunodeficiency virus type 1 tropism: Comparison of assays using replication-competent virus versus plasma-derived pseudotyped virions.

Hosoya N, Su Z, Wilkin T, Gulick RM, Flexner C, Hughes MD, Skolnik PR, Giguel F, Greaves WL, Coakley E, Kuritzkes DR.

J Clin Microbiol. 2009 Aug;47(8):2604-6. doi: 10.1128/JCM.00632-09. Epub 2009 Jun 3.


Quantitative deep sequencing reveals dynamic HIV-1 escape and large population shifts during CCR5 antagonist therapy in vivo.

Tsibris AM, Korber B, Arnaout R, Russ C, Lo CC, Leitner T, Gaschen B, Theiler J, Paredes R, Su Z, Hughes MD, Gulick RM, Greaves W, Coakley E, Flexner C, Nusbaum C, Kuritzkes DR.

PLoS One. 2009 May 25;4(5):e5683. doi: 10.1371/journal.pone.0005683.


Relationship between HIV coreceptor tropism and disease progression in persons with untreated chronic HIV infection.

Goetz MB, Leduc R, Kostman JR, Labriola AM, Lie Y, Weidler J, Coakley E, Bates M, Luskin-Hawk R; Long-Term Monitoring Study (CPCRA 060) and Terry Beirn Community Programs for Clinical Research on AIDS (CPCRA).

J Acquir Immune Defic Syndr. 2009 Mar 1;50(3):259-66. doi: 10.1097/QAI.0b013e3181989a8b. Erratum in: J Acquir Immune Defic Syndr. 2009 May 1;51(1):110.


Maintaining reduced viral fitness and CD4 response in HIV-infected patients with viremia receiving a boosted protease inhibitor.

Grant P, Taylor J, Cain P, Short W, Gallant J, Farthing C, Thal G, Coakley E, Zolopa A.

Clin Infect Dis. 2009 Mar 1;48(5):680-2. doi: 10.1086/597008.


Effect of alcohol septal ablation in patients with hypertrophic cardiomyopathy on the electrocardiographic pattern.

Coakley E, Steinberg DH, Tibrewala A, Asch F, Pichard AD, Kent KM, Lindsay J.

Am J Cardiol. 2008 Sep 1;102(5):621-4. doi: 10.1016/j.amjcard.2008.04.043. Epub 2008 Jun 18.


In vivo emergence of vicriviroc resistance in a human immunodeficiency virus type 1 subtype C-infected subject.

Tsibris AM, Sagar M, Gulick RM, Su Z, Hughes M, Greaves W, Subramanian M, Flexner C, Giguel F, Leopold KE, Coakley E, Kuritzkes DR.

J Virol. 2008 Aug;82(16):8210-4. doi: 10.1128/JVI.00444-08. Epub 2008 May 21.


Baseline HIV type 1 coreceptor tropism predicts disease progression.

Daar ES, Kesler KL, Petropoulos CJ, Huang W, Bates M, Lail AE, Coakley EP, Gomperts ED, Donfield SM; Hemophilia Growth and Development Study.

Clin Infect Dis. 2007 Sep 1;45(5):643-9. Epub 2007 Jul 20. Erratum in: Clin Infect Dis. 2007 Dec 15;45(12):1656.


Phase 2 study of the safety and efficacy of vicriviroc, a CCR5 inhibitor, in HIV-1-Infected, treatment-experienced patients: AIDS clinical trials group 5211.

Gulick RM, Su Z, Flexner C, Hughes MD, Skolnik PR, Wilkin TJ, Gross R, Krambrink A, Coakley E, Greaves WL, Zolopa A, Reichman R, Godfrey C, Hirsch M, Kuritzkes DR; AIDS Clinical Trials Group 5211 Team.

J Infect Dis. 2007 Jul 15;196(2):304-12. Epub 2007 Jun 5.


Association of HIV-1 replication capacity with treatment outcomes in patients with virologic treatment failure.

De Luca A, Weidler J, Di Giambenedetto S, Coakley E, Cingolani A, Bates M, Lie Y, Pesano R, Cauda R, Schapiro J.

J Acquir Immune Defic Syndr. 2007 Aug 1;45(4):411-7.


Supplemental Content

Loading ...
Support Center